Menopause: ou en sommes-nous trois ans apres la WHI? [Menopause: where are we three years beyond WHI?]

Détails

ID Serval
serval:BIB_B03674422A89
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Titre
Menopause: ou en sommes-nous trois ans apres la WHI? [Menopause: where are we three years beyond WHI?]
Périodique
Revue Médicale Suisse
Auteur⸱e⸱s
Reuse  C., Fraisse  T., Luzuy  F., de Ziegler  D.
ISSN
1660-9379
Statut éditorial
Publié
Date de publication
02/2006
Volume
2
Numéro
53
Pages
467, 469-70, 472 passim
Notes
English Abstract
Journal Article
Review --- Old month value: Feb 15
Résumé
The WHI triggered a great debate on Menopausal Hormonal Therapy. We now know that HT should not be used in cardio-vascular prevention. Many studies have yet been published regarding it's influence on breast cancers. Risks should be modulated in respect with the type of treatment and the targeted population. Only recently menopaused women or women suffering from invalidating menopausal symptoms should benefit from HT. When an HT is needed, the authors recommend the use of trans-cutaneous estrogens combined with natural oral progesterone. Every HT should be prescribed individually, according to the patient's aspirations and expectations.
Mots-clé
Breast Neoplasms/chemically induced Cardiovascular Diseases/chemically induced Female Health Promotion *Hormone Replacement Therapy/adverse effects Humans *Menopause Middle Aged *Women's Health
Pubmed
Création de la notice
28/02/2008 11:37
Dernière modification de la notice
20/08/2019 15:19
Données d'usage